The purpose of the study was to determine (1) if the exogenous administration of vitamin D analog, paricalcitol, can slow the progression of DN, (2) if paricalcitol can reduce the renal fibrosis due to hyperglycemia, and (3) if paricalcitol can reduce albuminuria via transcriptionally stimulating the expression of nephrin and podocin, a key slit diaphragm protein synthesized by podocytes [27–29]. This evidence concerns the gene NPHS1 and liver dysplastic nodule.